Targets and Emerging Therapies for Schizophrenia

New and emerging directions in pharmaceutical research to better treat schizophrenia.

Although the dopamine hypothesis has been the cornerstone of schizophrenia therapeutics, it is clear that dopamine-based approaches do not treat all aspects of the disease. Moreover, many schizophrenia patients fail to respond to current antipsychotics. Integrating chemistry, biology, and pharmacology, this book explores emerging directions in pharmaceutical research for drug targeting and discovery in order to find more effective treatments for schizophrenia, one of the most serious and widespread psychiatric diseases.

Targets and Emerging Therapies for Schizophrenia presents the basics of schizophrenia, drug targets for the disease, and potential new drugs and therapeutics. It begins with a discussion of prevalence and etiology. Then, it describes therapies such as dopamine agonists and phosphodiesterase (PDE) inhibitors as well as growing research aimed at addressing untreated symptoms. Next, the authors discuss receptor modulators, inhibitors, and targeting strategies for drug discovery. Both the neurobiological and chemical aspects of all major pharmacological targets are examined.

With contributions from an international team of pioneering pharmaceutical researchers, this book compiles the current knowledge in the field, setting the stage for new breakthroughs in the treatment of schizophrenia.

Publication Year: 2012
Edition: 1st
Author/Editor: Albert, Jeffrey S.; Wood, Michael W.
Publisher: Wiley
ISBN: 978-0-470-32282-6
Doody's Star Rating®: ★★★ Score: 67
Platform: Ovid
Product Type: Book
Speciality: Pharmaceutical Science, Pharmacology, Pharmacy, Psychiatry
Language: English
Pages: 494
Illustrations: 0